explore -WSS

explore

author：knowledge 2025-08-26 10:52:52 - browse：41

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Surge of respiratory disease in China has likely explanation

WSS

Congress must reauthorize a committee to support older Americans

Brazil's Jair Bolsonaro is barred from running for office until 2030

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Here's how to stay safe from wildfire smoke amid reduced air quality

PBM reforms clear House panel

UnitedHealth wins $3.3 billion takeover of Amedisys

leisure time

explore

Wikipedia

Alkermes shareholders re

NYU radiologists take on the challenge of expensive MRI machines

Supreme Court strikes down use of affirmative action

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Walensky prepares to leave CDC — and Congress — behind

Belarusian journalist sentenced to 4 years in prison as crackdown continues

How one medical school became remarkably diverse

Morphosys mixed study results for blood cancer drug

The cancer drug shortage isn’t new — and neither are the solutions

Anthos stroke drug appears safer than common blood thinner

hotspot

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Supreme Court rules employers must be more accommodating of religious observance

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

The strange history of BMI, the body mass index

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Hospitals look to new technology to keep health care workers safe

entertainment

entertainment

focus

hotspot